Authum Investment & Infrastructure Limited has informed the Exchange about Acquisition of Shares of OneSource Specialty Pharma Limited.
AIIL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Midcap 150 and 1.7 pts more than its Non Banking Financial Company (NBFC) peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Authum Investment & Infrastructure Limited (AIIL) is acquiring 39,27,000 shares (3.43% voting rights on a fully diluted basis) in OneSource Specialty Pharma Limited from Devicam Capital LLP and Pronomz Ventures LLP through a commercial transaction. The fair market value of the shares, based on NSE price as of June 13, 2025, aggregates to INR 2,028. OneSource Specialty Pharma, formerly Stelis Biopharma, is India's first specialty pharma CDMO with a net worth of Rs. 5,880 crores and FY25 turnover of Rs. 1,444.8 crores, showing rapid growth from Rs. 41 crores in FY23. The acquisition is outside AIIL's main line of business (investment and infrastructure), is not a related party transaction, and requires no regulatory approvals.
This is a significant strategic investment by AIIL, marking a diversification move into the high-growth pharmaceutical CDMO space. Since the stake is below the 5% threshold, no open offer is triggered. The investment could be positive for AIIL shareholders if OneSource continues its strong growth trajectory, though it represents exposure to a business outside the company's core operations.